Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO

Core Viewpoint - Inovio Pharmaceuticals, Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding its CELLECTRA device and its impact on FDA filing timelines [1] Group 1: Lawsuit Details - The class action lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - The class period for the lawsuit is from October 10, 2023, to December 26, 2025, with a deadline for participation set for April 7, 2026 [1] - Allegations include that Inovio's public statements were materially misleading due to manufacturing deficiencies that could delay the filing of a Biologics License Application (BLA) with the FDA [1] Group 2: Company Impact - The lawsuit claims that Inovio did not gather necessary evidence to support a priority review by the FDA, further compounding the misleading nature of its public statements [1] - Shareholders who purchased shares during the class period and suffered losses are encouraged to contact the DJS Law Group for potential recovery [1]